Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | TDP2 | O95551 | 3/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28472394 | 0.89 | BRD4 (0.61) | BRD4TDP2PDE4ACYP1A2TSHR | |
| SCHEMBL9202043 | 0.88 | ALDH1A1 (0.46) | BRD4CYP1A2TSHRKDM4EELANE | |
| SCHEMBL18132204 | 0.86 | BRD4 (0.58) | BRD4TDP2PDE4ACYP1A2TSHR | |
| SCHEMBL7908951 | 0.84 | BRD4 (0.57) | BRD4TDP2PDE4ACYP1A2TSHR | |
| SCHEMBL127810 | 0.84 | BRD4 (0.57) | BRD4TDP2PDE4ACYP1A2TSHR | |
| SCHEMBL30484547 | 0.84 | BRD4 (0.57) | BRD4TDP2PDE4ACYP1A2TSHR | |
| SCHEMBL30036150 | 0.84 | L3MBTL1 (0.55) | BRD4CYP1A2HTTKDM4EMAPT | |
| SCHEMBL1979301 | 0.84 | L3MBTL1 (0.55) | BRD4CYP1A2HTTKDM4EMAPT | |
| SCHEMBL1240286 | 0.82 | BRD4 (0.61) | BRD4TDP2PDE4ACYP1A2TSHR | |
| SCHEMBL29396522 | 0.82 | BRD4 (0.61) | BRD4TDP2PDE4ACYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240109899-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2022169921-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-11 | — | — | WO | disclosed |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2015158565-A1 | SUBSTITUTED PYRIDINE COMPOUNDS HAVING HERBICIDAL ACTIVITY | BASF SE (DE) | 2015-10-22 | — | — | WO | disclosed |
| EP-2578569-A1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| WO-2010052222-A1 | (DIHYDRO)NAPHTHYRIDINONE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010052222-A1 | (DIHYDRO)NAPHTHYRIDINONE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| US-7030120-B2 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | OHKURA NAOTO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6777414-B1 | INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | HRH2, HRH4, HRH1 | BRD4 693/4885TDP2 4868/4885PDE4A 3753/4885 |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | APOB, NCEH1, LIPC | BRD4 1725/4885TDP2 3757/4885PDE4A 2033/4885 |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | BRD4 1340/4885TDP2 4110/4885PDE4A 2677/4885 |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | BRD4 1233/4885TDP2 1955/4885PDE4A 1691/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | BRD4 1233/4885TDP2 1955/4885PDE4A 1691/4885 |
| US-20240109899-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | STING1, MAVS, IRF3 | BRD4 312/4885TDP2 247/4885PDE4A 80/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | BRD4 1751/4885TDP2 3830/4885PDE4A 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.